[Requests for cannabinoids for therapeutic use : how to support patients ?]

Area of Science:

• Pharmacology
• Medical Therapeutics

Background:

• Cannabis is utilized for symptom relief in conditions refractory to standard treatments, often as a last resort.
• Despite increasing patient interest and political support in Switzerland, practical access to medical cannabinoids is challenging.
• Barriers include limited robust medical indications, high costs (often unreimbursed), and insufficient physician knowledge regarding prescription.

Purpose of the Study:

• To evaluate the challenges and propose a pragmatic approach to medical cannabinoid access in Switzerland.
• To advocate for patient-centered care in managing illnesses with medical cannabis.

Main Methods:

• Qualitative analysis of current access barriers.
• Review of existing literature on cannabinoid efficacy and risks.
• Ethical considerations regarding patient autonomy and access rights.

Main Results:

• Medical use of cannabis is primarily for severe, treatment-resistant symptoms and quality of life improvement.
• Access is hindered by a lack of clear medical guidelines, financial burdens, and physician education deficits.
• Cannabinoids present low risks for medical applications.

Conclusions:

• A pragmatic approach respecting patients' right to access medical cannabinoids is advocated.
• Empowering patients to assess treatment effects can enhance the therapeutic relationship and patient engagement in illness management.
• Addressing systemic barriers is crucial for equitable access to cannabis-based therapies.